Korea’s Drive To Shorten IND Approval Times Focuses On Early-stage Trials
This article was originally published in PharmAsia News
KFDA is focusing on early-stage trials in a campaign to shorten IND approval times and draw more clinical trials to Korea
You may also be interested in...
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.